HOME >> MEDICINE >> NEWS
NIAID Stops AIDS Study Prematurely Because Drug 'Cocktail' Boosts Survival

dicine and director of the AIDS unit; Dr. David Wohl, research fellow in medicine; and research clinician Janet Groves.

Nationwide, researchers found 63 "disease progression events" -- including AIDS-related illnesses and deaths among patients receiving a combination of ZDV and 3TC, Eron said. Among patients receiving those two drugs and indinavir, they found only 33 such events.

"There were 18 deaths in the double-therapy arm of the study vs. eight deaths in the triple- therapy arm," he said. "No major differences were found in either safety or toxicity between the two treatments, and study medications were well-tolerated."

Indinavir, a protease inhibitor, works by preventing protease enzymes from cutting up proteins needed to form viruses, Eron explained. The envelope, or outer coating, of the virus still develops, but the core cannot, and therefore the resulting virus is not infectious.

Drugs such as ZDV and 3TC work by inhibiting an enzyme called reverse transcriptase. That enzyme enables the virus' genetic material, or RNA, to convert human genetic material known as DNA into more virus.

The Food and Drug Administration approved use of the combined ZDV and 3TC in November 1995, in part because of a national study Eron led and published in the New England Journal of Medicine. Indinavir has been approved for about a year.

"The people who should be thanked and congratulated for this study and others like it are the people who participated in the trials," Eron said. "They not only have done something that will improve their own care, but they have volunteered to do something that will clearly improve the care of many patients afterwards.

"Treatment with the triple-drug therapy is not easy because of the large number of pills patients have to take and the commitment they have to make to stick to the therapy," he said. "They are the real heroes here."

Glaxo-Wellcome Inc. of Research Triangle Park
'"/>

Contact: David Williamson
rdtokids@email.unc.edu
919-962-2091
University of North Carolina at Chapel Hill
25-Feb-1997


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID launches program to improve medical tools against emerging infectious diseases
8. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
9. NIAID rotavirus vaccine licensed for commercialization
10. Second NIAID SARS vaccine candidate helps mice fend off SARS
11. NIAID vaccine protects against SARS virus infection in mice

Post Your Comments:
(Date:10/25/2014)... Background: , In 1998 Bob Savage ... a pioneer in the field of establishing recovery community organizations. ... system and when he retired, he set out to answer ... service. , 1. Where are the people ... , 2. Can the recovery community be organized to ...
(Date:10/25/2014)... Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Diagnostics listing their product specification, capacity, Production ...
(Date:10/25/2014)... New York, New York (PRWEB) October 25, 2014 ... of transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) ... multidistrict litigation underway in U.S. District Court, Southern ... Motion for Summary Judgment on Punitive Damages in ... Florida plaintiffs. In a ruling issued on October ...
(Date:10/25/2014)... blood supply to an arm or a leg before heart ... according to a new study. "During heart surgery ... to be able to operate on it. After some time ... produce energy because it doesn,t get oxygen. When we shut ... an arm or a leg, the body prepares for an ...
(Date:10/25/2014)... (HealthDay News) -- Researchers who discovered antibiotics in ... cause for concern. The use of antibiotics ... human consumption contribute to the development of antibiotic-resistant ... information from the study. Each year in ... million people and kill about 23,000, according to ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today ... given the company permission to conduct an open-label study ... months of age with a diffuse intrinsic brainstem glioma ... five treatment groups based on their age and whether ... The primary study endpoint is a decrease in the ...
(Date:10/22/2014)... 2014  Cephasonics, a technology-innovation leader with a game-changing ... (cQuest Ultrasound Box™-1), the first product in a new ... by Cephasonics for purchase by companies to rebrand with ... be showcasing the cQUB-1 for the first time at ... Chongqing, China from October 23 to ...
(Date:10/22/2014)... Oct 22, 2014 Antigen Discovery Inc. (ADi), ... , announced the receipt of a National Institutes ... (SBIR) from the National Institute of Dental and Craniofacial Research ... of a Pan-HIV Protein Microarray Chip, which will contain ... subtypes and aid in the development of safe and ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
Cached News: